Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

In elderly patients 65 years of age or older with heart failure with reduced ejection fraction (HFrEF), regular use of sodium ...

For patients with acute MI at increased risk for HF, empagliflozin showed cardiorenal benefits and was safe to initiate early ...

In addition newer drugs like SGLT2 inhibitors, Angiotensin receptor neprisilyn inhibitors ,beta, blockers ,mineralocorticoid ...

Nurse practitioners form the key to providing culturally competent care, which improves outcomes for Asian American patients.

Avoid these 7 low-carb diet mistakes for better health with type 2 diabetes. Plus, learn tips for staying hydrated, eating ...

The field of cardiometabolic health has garnered substantial attention due to the increasing prevalence of type 2 diabetes ...

Patients with type 2 diabetes mellitus are at a higher risk of developing heart failure compared with the healthy population. In recent landmark clinical trials, sodium-glucose co-transporter 2 (SGLT2 ...

The human kidney is a masterclass in biological engineering. Responsible for filtering approximately 50 gallons of blood ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...